ClinicalTrials.gg
Status unknownNCT03332849Updated Nov 6, 2017

Multiple Ascending Dose Study of HM12470 in Type 1 and Type 2 Diabetes Mellitus

A Phase 1 interventional study of HM12470 in Type1 Diabetes Mellitus and Type2 Diabetes Mellitus, sponsored by Hanmi Pharmaceutical Company Limited. Status unknown at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-11-06.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 1, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Nov 2017), so the status shown — last known as Active, not recruiting — may be out of date.

From the registry’s dates

  • Registered 2 years 2 months after the study started (first participant enrolled Jul 2015, registered Oct 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 191 open to participants now, 259 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Enrollment
468th of 1,242
60 · median 40
Started
2015
with 56 others
Phase 1
147 of 1,458
11 open now
Registered
806th of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 468th largest by enrollment of the 1,242 interventional ones that give a count, is one of 57 that started in 2015, is one of 147 in phase 1, and was the 806th registered.

Diabetes Mellitus, Type 1

3,756 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

191 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

186 more — sign in →

All 191 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 1 and Type 2 diabetes mellitus

03

Conditions studied

  • Type1 Diabetes Mellitus
  • Type2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • T1DM or T2DM
  • Female subjects must be non-pregnant and non-lactating

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women
  • Participation in an study within 30 days prior to dosing
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Cohort 1

    T1DM: Multiple dose subcutaneous administration

    Biological: HM12470

  • Experimental
    Cohort 2

    T1DM: Multiple dose subcutaneous administration

    Biological: HM12470

  • Experimental
    Cohort 3

    T2DM: Multiple dose subcutaneous administration

    Biological: HM12470

  • Experimental
    Cohort 4

    T2DM: Multiple dose subcutaneous administration

    Biological: HM12470

Interventions

  • BiologicalHM12470

    HM12470 is a long-acting insulin analogue

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events

    An adverse event is any undesirable and unintended medical event occurring to a subject in a clinical study, whether or not related to the investigational products.

    Time frame: 1 month

Secondary outcomes

  1. Cmax of HM12470

    - Maximum concentration of HM12470 over the entire dosing period

    Time frame: 1 month

  2. AUC of HM12470

    - Area Under the Curve of HM12470 over the entire dosing period

    Time frame: 1 month

07

Study locations

1 site
  • Hanmi Investigative Site
    Chula Vista, California 91911, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2015 (actual). Primary completion is estimated for Apr 2018, 33 months after the start.

Of 97 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's planned 33 months is above that.

Counting every sponsor, half of 152 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2017
First posted
Nov 6, 2017
StartActual
Jul 28, 2015
Primary completionEst.
Apr 30, 2018
CompletionEst.
Apr 30, 2018
Last update
Nov 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03332849
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Jul 28, 2015
Primary completion
Apr 30, 2018 (estimated)
Completion
Apr 30, 2018 (estimated)
Last update
Nov 6, 2017

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HM12470

Start the discussion